Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.

You may also be interested in...

Valeant Racks Up FDA Letters Criticizing Its Promotional Materials

FDA says Valiant’s webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated claims it is superior to Valtrex. It is the fifth letter the agency has sent the company in the past year.

Atralin Acne Gel Awarded “A+” In Valeant Ad, But FDA Sends Promo To Back Of The Class

A clever marketing graphic is dinged because it comes in the context of unjustified superiority claims.

Copaxone Promos Can’t List Risks Product Doesn’t Have, Especially Incorrectly, FDA Warns

The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts